Is Abbott Laboratories (ABT) Fairly Valued After Its FDA Win And Oncodetect Launch?

Simply Wall St.11-10

Abbott Laboratories (ABT) just picked up a unique FDA approval for its Amplatzer Paraclose PVL Occluder and rolled out its next-generation Oncodetect MRD test, expanding its presence in complex heart ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682338649?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/247483-card/1788988990542","is_english":true,"pubTime":"2026-11-10 01:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682338649","market":"sg","top_or_hot":-1,"title":"Is Abbott Laboratories (ABT) Fairly Valued After Its FDA Win And Oncodetect Launch?","media":"Simply Wall St.","content":"<div>\n<p>Abbott Laboratories (ABT) just picked up a unique FDA approval for its Amplatzer Paraclose PVL Occluder and rolled out its next-generation Oncodetect MRD test, expanding its presence in complex heart ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-fairly-valued-after-its-fda-win-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Abbott Laboratories (ABT) Fairly Valued After Its FDA Win And Oncodetect Launch?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Abbott Laboratories (ABT) Fairly Valued After Its FDA Win And Oncodetect Launch?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-10 01:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-fairly-valued-after-its-fda-win-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Abbott Laboratories (ABT) just picked up a unique FDA approval for its Amplatzer Paraclose PVL Occluder and rolled out its next-generation Oncodetect MRD test, expanding its presence in complex heart ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-fairly-valued-after-its-fda-win-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJT1NW94.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-fairly-valued-after-its-fda-win-a","article_id":"2682338649","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/247483-card/1788988990542"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-fairly-valued-after-its-fda-win-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682338649","pubTimestamp":1794245672,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 9, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","PJP":"INVESCO PHARMACEUTICALS ETF","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","SG9999002232.USD":"Allianz Global High Payout USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","LU1670627923.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) ACC","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","BK4581":"高盛持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","ABT.AU":"Abundant Produce","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","IHI":"iShares Dow Jones U.S. Medical D","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4566":"资本集团","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4592":"伊斯兰概念","LU1670628061.USD":"M&G (LUX) NORTH AMERICAN DIVIDEND \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","TMED":"T. Rowe Price Health Care ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4568":"美国抗疫概念","LABU":"三倍做多标普生物-Direxion","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","ABT":"雅培","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H"},"translate_title":"雅培实验室 (ABT) 在 FDA 获胜并推出 Oncodetect 后估值是否合理？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IHI":0.6,"PJP":0.6,"ABT.AU":1.5,"LABU":1.5,"ABT":1.5,"TMED":0.6},"content_text":"Abbott Laboratories (ABT) just picked up a unique FDA approval for its Amplatzer Paraclose PVL Occluder and rolled out its next-generation Oncodetect MRD test, expanding its presence in complex heart procedures and cancer monitoring. Recent headlines in cardiology and cancer diagnostics have arrived against a mixed share price backdrop for Abbott Laboratories, with the stock at US$109.93 after a 10.37% 1 month share price return but a decline of 11.48% for the year to date. Over the last year investors have seen the share price fall enough for total shareholder return to decline 10.51%, yet a 22.23% total shareholder return over three years points to earlier gains that contrast with the weaker recent momentum. Short term moves, including a 3.23% drop on the day, suggest investors are still weighing new product approvals, clinical data and device recall headlines against the longer record of compounding returns. Scan how Abbott Laboratories stacks up against other complex-care players by reviewing the hand-picked 35 healthcare AI stocks riding advances in cardiology, diagnostics and data-driven medicine. Abbott Laboratories now trades about 7% below the average analyst target and at a steeper implied discount to some fair value estimates. After the recent slide, is that caution fully earned, or is it overly harsh on the new product momentum? AdvertisementMost Popular Narrative: 9% Undervalued On the Simply Wall St analyst consensus Narrative, Abbott Laboratories carries a fair value estimate of $120.26 compared with the last close at $109.93. That view ties the gap to future earnings power rather than recent share price volatility. The main thing that has to go right is that Abbott Laboratories continues to convert its medical technology pipeline in areas like continuous glucose monitoring, electrophysiology and cancer diagnostics into sustained sales growth and margin expansion, while managing Nutrition legal and regulatory risks. See why 198 investors see Abbott Laboratories as 9% undervalued. Result: Fair Value of $120.26 (UNDERVALUED) Still, Abbott Laboratories faces real pressure points, with ongoing Nutrition legal settlements and higher Libre expansion costs, both capable of squeezing the margin story that the narrative leans on. Find out about the key risks to this Abbott Laboratories narrative. Another View on Abbott Laboratories Valuation Multiples tell a different story for Abbott Laboratories. The stock trades on a P/E of 40.7x, which is higher than both the US Medical Equipment industry at 25.7x and its peer average at 38x, and only slightly above the fair ratio of 40.1x that the market could move toward. That points to less obvious upside and more pressure on execution to justify the current tag. How comfortable are you with paying this kind of premium for Abbott Laboratories today? To see how that premium lines up against the underlying numbers and risks, take a closer look at the valuation breakdown, including the fair ratio context, in See what the numbers say about this price — find out in our valuation breakdown. NYSE:ABT P/E Ratio as at Nov 2026Next Steps Mixed signals around Abbott Laboratories can feel messy, so review both the upside and the concerns promptly and then decide what stacks up for you with 2 key rewards and 4 important warning signs Looking for more investment ideas beyond Abbott Laboratories? Do not stop with Abbott Laboratories. Put this analysis in context by lining it up against other opportunities that match your goals and risk comfort.  Target resilient opportunities by scanning a 31 resilient stocks with low risk scores that aims to prioritize balance sheet strength and steadier return profiles over headline excitement. Hunt for value by lining up companies in a 40 high quality undervalued stocks that focuses on strong fundamentals at prices that may not fully reflect them. Spot under-the-radar potential through a 19 high quality undiscovered gems that highlights quality businesses investors are not widely talking about yet.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682338649","isCrawlerRequest":true}